United States· US:0006-4045_32651aaa-4a24-4e44-8d7f-9960705a382f
GARDASIL
A medicinal product containing human papillomavirus type 6 l1 capsid protein antigen; human papillomavirus type 11 l1 capsid protein antigen; human papillomavirus type 16 l1 capsid protein antigen; human papillomavirus type 18 l1 capsid protein antigen, registered in United States by Merck Sharp & Dohme LLC.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- HUMAN PAPILLOMAVIRUS TYPE 6 L1 CAPSID PROTEIN ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 11 L1 CAPSID PROTEIN ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 16 L1 CAPSID PROTEIN ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 18 L1 CAPSID PROTEIN ANTIGEN
- Manufacturer
- Merck Sharp & Dohme LLC
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc1100064045001 VIAL, SINGLE-DOSE in 1 CARTON (0006-4045-00) / .5 mL in 1 VIAL, SINGLE-DOSE (0006-4045-01)
- ndc11000640454110 VIAL, SINGLE-DOSE in 1 CARTON (0006-4045-41) / .5 mL in 1 VIAL, SINGLE-DOSE (0006-4045-01)
- ndc110006-4045-00
- ndc110006-4045-41
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Human papillomavirus type 6 l1 capsid protein antigen; human papillomavirus type 11 l1 capsid protein antigen; human papillomavirus type 16 l1 capsid protein antigen; human papillomavirus type 18 l1 capsid protein antigen in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8bfa7af6-8899-48d0-a0d3-28d7f9d27375 GET /v1/drugs/8bfa7af6-8899-48d0-a0d3-28d7f9d27375?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAMUSCULAR",
"source": "ndc",
"strength": "20; 40; 40; 20",
"substance": "HUMAN PAPILLOMAVIRUS TYPE 6 L1 CAPSID PROTEIN ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 11 L1 CAPSID PROTEIN ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 16 L1 CAPSID PROTEIN ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 18 L1 CAPSID PROTEIN ANTIGEN",
"productndc": "0006-4045",
"dosage_form": "INJECTION, SUSPENSION",
"dea_schedule": null,
"strength_unit": "ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL",
"application_number": "BLA125126",
"marketing_category": "BLA"
}See everything about human papillomavirus type 6 l1 capsid protein antigen; human papillomavirus type 11 l1 capsid protein antigen; human papillomavirus type 16 l1 capsid protein antigen; human papillomavirus type 18 l1 capsid protein antigen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.